ArticlePharmaceutics2023

SGLT2 Inhibitor-Dapagliflozin Attenuates Diabetes-Induced Renal Injury by Regulating Inflammation through a CYP4A/20-HETE Signaling Mechanism.

Batoul Dia et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.